PMID- 7778058
OWN - NLM
STAT- MEDLINE
DCOM- 19950712
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 77
IP  - 5
DP  - 1995 Mar 1
TI  - Interferon-gamma modulates the fibrinolytic response in cultured human 
      endothelial cells.
PG  - 431-40
AB  - The fibrinolytic potential of the endothelial cells gives important 
      antithrombotic properties to the vascular wall. Thrombosis is a frequent 
      complication to atherosclerosis and other conditions where inflammatory mediators 
      are present in the vascular wall. Inflammatory agents like lipopolysaccharide 
      (LPS) and tumor necrosis factor-alpha (TNF alpha) have been demonstrated to 
      modulate the expression of fibrinolytic factors in cultured endothelial cells. In 
      the present study the expression of tissue-type plasminogen activator (t-PA), 
      urokinase plasminogen activator (u-PA) and plasminogen activator inhibitors-1 and 
      -2 (PAI-1 and PAI-2) antigen in conditioned medium from cultured human umbilical 
      vein (HUVEC) and human saphenous vein (HSVEC) endothelial cells was investigated 
      under basal conditions and after stimulation with LPS, TNF alpha, 
      interferon-gamma (IFN-gamma) or interleukin-6 (IL-6) alone or in combinations. 
      Stimulation with LPS or TNF alpha increased the expression of PAI-1, u-PA and 
      PAI-2 in HUVEC and HSVEC, while the t-PA response differed between the two cell 
      types. The effects of TNF alpha were modulated by IFN-gamma but not by IL-6. The 
      increased expression of u-PA after stimulation with TNF alpha was reduced by 
      IFN-gamma. In contrast, TNF alpha-induced expression of PAI-2 was synergistically 
      increased by addition of IFN-gamma. These effects of IFN-gamma represent 
      additional mechanisms by which inflammatory mediators may turn the fibrinolytic 
      potential of the endothelium in a prothrombotic direction.
FAU - Arnman, V
AU  - Arnman V
AD  - Department of Surgery, Sahlgrenska University Hospital, University of Goteborg, 
      Sweden.
FAU - Stemme, S
AU  - Stemme S
FAU - Rymo, L
AU  - Rymo L
FAU - Risberg, B
AU  - Risberg B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Plasminogen Inactivators)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 3.4.21.- (Plasminogen Activators)
SB  - IM
MH  - Adult
MH  - Cells, Cultured
MH  - Endothelium, Vascular/cytology/*drug effects/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Infant, Newborn
MH  - Interferon-gamma/*pharmacology
MH  - Interleukin-6/pharmacology
MH  - Lipopolysaccharides/pharmacology
MH  - Plasminogen Activators/drug effects/*metabolism
MH  - Plasminogen Inactivators/*metabolism
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - Umbilical Veins/cytology
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
AID - 0049-3848(95)93879-5 [pii]
AID - 10.1016/0049-3848(95)93879-5 [doi]
PST - ppublish
SO  - Thromb Res. 1995 Mar 1;77(5):431-40. doi: 10.1016/0049-3848(95)93879-5.